Alembic Pharmaceuticals533573Subsidiary or JV
Step-down wholly owned subsidiary Alvesta Pharmaceuticals FZCO incorporated in Dubai, UAE
Alembic Global Holding SA, a WOS of the Company, has incorporated Alvesta Pharmaceuticals FZCO in Dubai, UAE.
By ScoutQuest · · 1 min read
100%Control through AGH
- Subscription Consideration
- AED 100,000 for 100 shares of AED 1,000 each
- Control / Ownership
- 100% control via AGH
- Incorporation Date
- 1st September, 2026
What was announced
- Alembic Global Holding SA, a wholly owned subsidiary of the Company, has incorporated its own wholly owned subsidiary named Alvesta Pharmaceuticals FZCO in Dubai, United Arab Emirates.
- Date of incorporation is 1st September, 2026; the Company received intimation of it on 19th October, 2026.
- Alvesta Pharmaceuticals FZCO is therefore a step-down wholly owned subsidiary of the Company.
Why the entity was set up
- The line of business stated is pharmaceuticals.
- Its stated purpose is to explore new business opportunities and to promote, sale and distribute pharmaceutical product(s) of the Company.
Ownership and cost
- Nature of consideration: cash consideration.
- Cost of subscription: AED 100,000 (Arab Emirates Dirham One Lakh Only).
- 100 shares of AED 1,000 each are subscribed by AGH.
- Percentage of control is 100% through AGH.
Other details in the disclosure
- Against governmental or regulatory approvals required for the incorporation, the update records Not Applicable.
- The holding company is Alembic Global Holding SA (AGH), itself a wholly owned subsidiary of the Company; the relation to the listed entity is step-down wholly owned subsidiary.
How to read this
- This is a structure update about a new overseas step-down subsidiary, with the entire holding routed through AGH.
- The stated role is distribution, promotion and exploring business opportunities for the Company's pharmaceutical products, with the UAE as the country of incorporation.
- The subscription amount stated is AED 100,000, paid in cash as per the update.
Also from Alembic Pharmaceuticals
USFDA final approval received for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%
17 Oct 2026
Alembic Pharmaceuticals Ltd shareholder sells 0.07% stake, holding falls to 2.97%
29 Sep 2026
More numbers
- Cost of subscriptionAED 100,000
- Price per share subscribedAED 1,000
- Number of shares allotted to AGH100 shares
- Percentage of control through AGH100%
Source: BSE · 19 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.